Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer

Introduction: Antibody drug conjugates (ADCs) represent a developing class of anticancer therapeutics which are designed to selectively deliver a cytotoxic payload to tumors, while limiting systemic toxicity to healthy tissues. There are several ADCs which are currently in various stages of clinical development for the treatment of gastrointestinal malignancies.Areas covered: We discuss the biologic rationale and review the clinical experience...